Sort   by:  
 Page size 
ProteomicsA T-cell receptor targeting RUNX1 frameshift mutations in acute myeloid leukemia
Runt-related transcription factor 1 (RUNX1) is a key regulator of hematopoietic differentiation. Disruption of RUNX1 in acute myeloid leukemia (AML) induces a maturation arrest and early myeloid progenitor phenotype. RUNX1 mutations occur in 10-15% of AML and are associated with poor prognosis. One-...
ORGANISM(S): Homo sapiens (Human) 
2025-07-31 | PXD062938 | Pride
Tcr-based immunotherapy Hla-peptidomics Runx1 Aml 
ProteomicsHotspot DNMT3A and IDH1/2 Mutations in Acute Myeloid Leukemia and Their Relevance as Targets for Immunotherapy
DNA methyltransferase 3A (DNMT3A) and isocitrate dehydrogenase 1 & 2 (IDH1/2) are genes involved in epigenetic regulation, each mutated in 7-23% of acute myeloid leukemia (AML). Here, we investigated whether hotspot mutations in these genes encode neoantigens that can be targeted by immunotherapy. F...
ORGANISM(S): Homo sapiens (Human) 
2024-06-23 | PXD050560 | Pride
Hotspot mutation Iso-citrate dehydrogenase 2 Dna methyltransferase 3a Cancer immunotherapy Acute myeloid leukemia Neoantigen T-cell therapy 
Sort   by:  
 Page size